Portfolio company
Gloucester Pharmaceuticals
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops oncology drug candidates, including romidepsin, for the treatment of patients with cutaneous and peripheral T-cell lymphoma.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Proteolix
This biopharmaceutical company develops proteasome-inhibitor drugs for patients with multiple myeloma and other cancer types.
Pharmacyclics
This company develops small-molecule medicines for patients with cancer and immune-mediated diseases.
Tisbury Pharmaceutical
This company develops drug therapies to treat glaucoma and ocular hypertension for patients with these vision-threatening conditions.
Chromacure
This company develops small molecule therapeutics for oncology patients to address unmet clinical needs in cancer treatment.
Lutris Pharma
The company develops topical therapies to treat skin toxicities in cancer patients undergoing epidermal growth factor receptor inhibitor or radiation treatments.
Enterome
This biopharmaceutical company develops microbiome-derived immunotherapies for patients with solid and liquid cancers, including non-Hodgkin lymphoma, and inflammatory diseases.
Depomed
This pharmaceutical company develops and markets branded prescription medicines for patients with neurology, oncology, and inflammatory conditions.
CARGO Therapeutics
This biotechnology company develops engineered cell therapies to treat cancer patients with relapsed or resistant lymphoma.